Order Article Reprints

Schild Y, Bosserhoff J, Droege F, Littwitz-Salomon E, Fandrey J, Wrobeln A. Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor Improves Leukocyte Energy Metabolism in Hereditary Hemorrhagic Telangiectasia. Life. 2023; 13(8):1708. https://doi.org/10.3390/life13081708

Schild, Yves, Jonah Bosserhoff, Freya Droege, Elisabeth Littwitz-Salomon, Joachim Fandrey, and Anna Wrobeln. 2023. "Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor Improves Leukocyte Energy Metabolism in Hereditary Hemorrhagic Telangiectasia" Life 13, no. 8: 1708. https://doi.org/10.3390/life13081708

Schild, Y., Bosserhoff, J., Droege, F., Littwitz-Salomon, E., Fandrey, J., & Wrobeln, A. (2023). Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor Improves Leukocyte Energy Metabolism in Hereditary Hemorrhagic Telangiectasia. Life, 13(8), 1708. https://doi.org/10.3390/life13081708